IKT
#3411
Inhibikase Therapeutics, Inc. - Common Stock
2.0 7 USD
0.00%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
Year Range
Daily Change
+0.49%
Monthly Change
+23.95%
6 month change
+24.70%
Year Change
+15.00%
Previous Close
2.0 6
Open
2.0 7
Low
2.0 5
High
2.1 0
Volume
480
Financials
- Market Capitalization 273.31 M
- Employee 35
- Founded 2008
- CEO N/A
- Website www.inhibikase.com
- Headquarter Delaware, United States
- FIGI BBG005TP2339
- Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-3.82
Price to sales ratio
43.33
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 3398 |  NAGE Niagen Bioscience, Inc. - Common Stock | 3.47 USD | +5.47% | +2.97% | -1.42% | -30.32% | 276.37 M USD | ||
| 3405 |  SABS SAB Biotherapeutics, Inc. - Common Stock | 3.62 USD | +0.56% | -3.98% | -7.18% | +29.29% | 276.80 M USD | ||
| 3420 |  ALXO ALX Oncology Holdings Inc. - Common Stock | 2.04 USD | +2.00% | -12.45% | +28.30% | +334.04% | 274.51 M USD | ||
| 3422 |  MGNX MacroGenics, Inc. - Common Stock | 4.33 USD | +0.93% | -7.08% | +4.34% | +188.67% | 275.23 M USD |
Frequently asked questions about Inhibikase Therapeutics, Inc. - Common Stock
What is the Inhibikase Therapeutics, Inc. - Common Stock stock price today?
The current price of Inhibikase Therapeutics, Inc. - Common Stock (IKT) is 2.07. Over the past 24 hours, the stock has changed by +0.49%. Follow the IKT chart for real-time price dynamics.
What is the stock ticker of Inhibikase Therapeutics, Inc. - Common Stock?
Inhibikase Therapeutics, Inc. - Common Stock trades under the ticker IKT. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Inhibikase Therapeutics, Inc. - Common Stock stock going up?
IKT has changed by 0.00% over the last week, +23.95% over the last month, and +15.00% over the last year. Review the chart to see whether the current move is part of a broader trend.
What was Inhibikase Therapeutics, Inc. - Common Stock net income for the last quarter?
Inhibikase Therapeutics, Inc. - Common Stock reported net income of -16.38 M for the last quarter. The previous quarter showed -12.73 M, which means net income changed by -28.63%.
How many employees does Inhibikase Therapeutics, Inc. - Common Stock have?
As of the latest available data, Inhibikase Therapeutics, Inc. - Common Stock has 35 employees. Workforce size can provide additional context about the company's scale and operations.
What is Inhibikase Therapeutics, Inc. - Common Stock EBITDA?
Inhibikase Therapeutics, Inc. - Common Stock EBITDA is -16.38 M, and its EBITDA margin is -1 121.15%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Inhibikase Therapeutics, Inc. - Common Stock stock?
You can buy Inhibikase Therapeutics, Inc. - Common Stock (IKT) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Inhibikase Therapeutics, Inc. - Common Stock stock?
Investing in Inhibikase Therapeutics, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the IKT chart and related analysis on metatrader.com as part of your research.